

Robert H Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/508163/publications.pdf>

Version: 2024-02-01

172
papers

34,129
citations

10070

75
h-index

5244

171
g-index

186
all docs

186
docs citations

186
times ranked

29450
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. <i>Nature</i> , 1993, 362, 59-62.	13.7	6,331
2	Decoding ALS: from genes to mechanism. <i>Nature</i> , 2016, 539, 197-206.	13.7	1,533
3	Amyotrophic Lateral Sclerosis. <i>New England Journal of Medicine</i> , 2017, 377, 162-172.	13.9	1,264
4	Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. <i>Nature Genetics</i> , 1996, 13, 43-47.	9.4	1,153
5	Molecular biology of amyotrophic lateral sclerosis: insights from genetics. <i>Nature Reviews Neuroscience</i> , 2006, 7, 710-723.	4.9	984
6	Mutant dynactin in motor neuron disease. <i>Nature Genetics</i> , 2003, 33, 455-456.	9.4	884
7	Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. <i>Nature Genetics</i> , 1998, 20, 31-36.	9.4	857
8	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. <i>Science</i> , 2015, 347, 1436-1441.	6.0	823
9	Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis. <i>Journal of Neurochemistry</i> , 1997, 69, 2064-2074.	2.1	671
10	A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. <i>Nature Genetics</i> , 2001, 29, 166-173.	9.4	635
11	ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2006, 38, 411-413.	9.4	617
12	Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. <i>Nature Neuroscience</i> , 2010, 13, 1396-1403.	7.1	600
13	Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons. <i>Cell Reports</i> , 2014, 7, 1-11.	2.9	583
14	dSarm/Sarm1 Is Required for Activation of an Injury-Induced Axon Death Pathway. <i>Science</i> , 2012, 337, 481-484.	6.0	558
15	Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. <i>Nature</i> , 2012, 488, 499-503.	13.7	522
16	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
17	Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. <i>Human Molecular Genetics</i> , 2009, 18, 472-481.	1.4	512
18	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1043-1048.	9.4	494

#	ARTICLE	IF	CITATIONS
19	XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. <i>Genes and Development</i> , 2009, 23, 2294-2306.	2.7	463
20	Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. <i>Human Molecular Genetics</i> , 2010, 19, 4160-4175.	1.4	447
21	Pathways Disrupted in Human ALS Motor Neurons Identified through Genetic Correction of Mutant SOD1. <i>Cell Stem Cell</i> , 2014, 14, 781-795.	5.2	392
22	Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 69.	3.0	367
23	A Met-to-Val mutation in the skeletal muscle Na ⁺ channel β -subunit in hyperkalaemic periodic paralysis. <i>Nature</i> , 1991, 354, 387-389.	13.7	356
24	Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2009, 41, 1083-1087.	9.4	344
25	Dysferlin Interacts with Annexins A1 and A2 and Mediates Sarcolemmal Wound-healing. <i>Journal of Biological Chemistry</i> , 2003, 278, 50466-50473.	1.6	336
26	Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. <i>Journal of Neurochemistry</i> , 2005, 93, 1087-1098.	2.1	315
27	Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. <i>Neuron</i> , 2014, 84, 324-331.	3.8	308
28	miRNA malfunction causes spinal motor neuron disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13111-13116.	3.3	299
29	Inhibition of ICE slows ALS in mice. <i>Nature</i> , 1997, 388, 31-31.	13.7	298
30	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. <i>Neuron</i> , 2014, 83, 1043-1050.	3.8	289
31	SPTLC1 is mutated in hereditary sensory neuropathy, type 1. <i>Nature Genetics</i> , 2001, 27, 261-262.	9.4	284
32	SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. <i>Nature Neuroscience</i> , 1999, 2, 427-433.	7.1	282
33	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. <i>Nature Medicine</i> , 2012, 18, 1418-1422.	15.2	269
34	Emerging mechanisms of molecular pathology in ALS. <i>Journal of Clinical Investigation</i> , 2015, 125, 1767-1779.	3.9	244
35	Respiratory dysfunction and management in spinal cord injury. <i>Respiratory Care</i> , 2006, 51, 853-68;discussion 869-70.	0.8	240
36	Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2003, 4, 62-73.	1.4	234

#	ARTICLE	IF	CITATIONS
37	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	9.4	223
38	Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. <i>Nature Genetics</i> , 1994, 7, 425-428.	9.4	221
39	Neonatal Neuronal Circuitry Shows Hyperexcitable Disturbance in a Mouse Model of the Adult-Onset Neurodegenerative Disease Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2008, 28, 10864-10874.	1.7	219
40	Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. <i>Neuron</i> , 2015, 88, 902-909.	3.8	219
41	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1037-1042.	9.4	218
42	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. <i>Lancet Neurology</i> , The, 2010, 9, 986-994.	4.9	205
43	The C9ORF72 expansion mutation is a common cause of ALS+FTD in Europe and has a single founder. <i>European Journal of Human Genetics</i> , 2013, 21, 102-108.	1.4	201
44	Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. <i>Journal of Neurochemistry</i> , 2005, 95, 1461-1471.	2.1	191
45	A Yeast Model of FUS/TLS-Dependent Cytotoxicity. <i>PLoS Biology</i> , 2011, 9, e1001052.	2.6	191
46	Peripheral neuropathy in the acquired immunodeficiency syndrome. <i>Annals of Neurology</i> , 1988, 23, 485-492.	2.8	186
47	TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. <i>Nature Neuroscience</i> , 2018, 21, 552-563.	7.1	181
48	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	179
49	Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9004-9009.	3.3	177
50	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Nature Communications</i> , 2016, 7, 11253.	5.8	174
51	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2011, 70, 964-973.	2.8	168
52	Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. <i>Human Molecular Genetics</i> , 2004, 13, 1999-2010.	1.4	166
53	Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. <i>Brain</i> , 2016, 139, 1094-1105.	3.7	155
54	Genetics of Amyotrophic Lateral Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a024125.	2.9	151

#	ARTICLE	IF	CITATIONS
55	<i>SOD1</i> Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. <i>New England Journal of Medicine</i> , 2020, 383, 151-158.	13.9	151
56	Rapid Communication: Cu/Zn Superoxide Dismutase Activity in Familial and Sporadic Amyotrophic Lateral Sclerosis. <i>Journal of Neurochemistry</i> , 1994, 62, 384-387.	2.1	143
57	Dysferlin in Membrane Trafficking and Patch Repair. <i>Traffic</i> , 2007, 8, 785-794.	1.3	138
58	Phase 2 study of sodium phenylbutyrate in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 99-106.	2.3	135
59	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	129
60	Mutations in the N-terminal Actin-Binding Domain of Filamin C Cause a Distal Myopathy. <i>American Journal of Human Genetics</i> , 2011, 88, 729-740.	2.6	124
61	Amyotrophic Lateral Sclerosis. <i>New England Journal of Medicine</i> , 2017, 377, 1602-1602.	13.9	118
62	Amyotrophic lateral sclerosis: Problems and prospects. <i>Annals of Neurology</i> , 2013, 74, 309-316.	2.8	117
63	Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1998, 43, 645-653.	2.8	109
64	ALS-linked protein disulfide isomerase variants cause motor dysfunction. <i>EMBO Journal</i> , 2016, 35, 845-865.	3.5	109
65	Superoxide Dismutase Concentration and Activity in Familial Amyotrophic Lateral Sclerosis. <i>Journal of Neurochemistry</i> , 1995, 64, 2366-2369.	2.1	101
66	Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves Activation of p38 MAP Kinase. <i>PLoS ONE</i> , 2013, 8, e65235.	1.1	100
67	Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. <i>Journal of Neurophysiology</i> , 2013, 109, 2803-2814.	0.9	99
68	A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and miyoshi myopathy. <i>Annals of Neurology</i> , 2002, 51, 129-133.	2.8	98
69	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. <i>Nature Medicine</i> , 2021, 27, 1197-1204.	15.2	96
70	NurOwn, phase 2, randomized, clinical trial in patients with ALS. <i>Neurology</i> , 2019, 93, e2294-e2305.	1.5	95
71	<i>C9orf72</i> and <i>UNC13A</i> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis. <i>Annals of Neurology</i> , 2014, 76, 120-133.	2.8	91
72	Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8209-8214.	3.3	88

#	ARTICLE	IF	CITATIONS
73	Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. <i>Neurobiology of Aging</i> , 2015, 36, 1602.e17-1602.e27.	1.5	87
74	Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6209-E6218.	3.3	85
75	Therapeutic rAAVrh10 Mediated <i>SOD1</i> Silencing in Adult <i>SOD1^{G93A}</i> Mice and Nonhuman Primates. <i>Human Gene Therapy</i> , 2016, 27, 19-31.	1.4	85
76	Randomized trial of <i>scp</i> -serine in patients with hereditary sensory and autonomic neuropathy type 1. <i>Neurology</i> , 2019, 92, e359-e370.	1.5	83
77	Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24213-24223.	3.3	83
78	Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2014, 23, 668-681.	1.4	81
79	Apolipoprotein E ϵ 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1995, 38, 460-463.	2.8	80
80	Sequence variants in human neurofilament proteins: Absence of linkage to familial amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1996, 40, 603-610.	2.8	78
81	Mitochondrial damage revealed by immunoselection for ALS-linked misfolded <i>SOD1</i> . <i>Human Molecular Genetics</i> , 2013, 22, 3947-3959.	1.4	78
82	The distinct genetic pattern of ALS in Turkey and novel mutations. <i>Neurobiology of Aging</i> , 2015, 36, 1764.e9-1764.e18.	1.5	78
83	Adeno-associated virus delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. <i>Annals of Neurology</i> , 2016, 79, 687-700.	2.8	78
84	A randomized trial of mexiletine in ALS. <i>Neurology</i> , 2016, 86, 1474-1481.	1.5	72
85	Suppression of mutant <i>C9orf72</i> expression by a potent mixed backbone antisense oligonucleotide. <i>Nature Medicine</i> , 2022, 28, 117-124.	15.2	72
86	Age-Dependent TDP-43-Mediated Motor Neuron Degeneration Requires GSK3, hat-trick, and xmas-2. <i>Current Biology</i> , 2015, 25, 2130-2136.	1.8	71
87	Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients. <i>Gene</i> , 2015, 566, 158-165.	1.0	70
88	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. <i>Neurobiology of Aging</i> , 2013, 34, 357.e7-357.e19.	1.5	69
89	Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. <i>Human Molecular Genetics</i> , 2017, 26, ddw429.	1.4	67
90	Toxic mutants in Charcot's sclerosis. <i>Nature</i> , 1995, 378, 342-343.	13.7	64

#	ARTICLE	IF	CITATIONS
91	Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer. <i>PLoS ONE</i> , 2012, 7, e39233.	1.1	64
92	Longitudinal biomarkers in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1103-1116.	1.7	62
93	Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	59
94	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. <i>Neurobiology of Aging</i> , 2018, 71, 266.e1-266.e10.	1.5	59
95	Association of a Locus in the <i>CAMTA1</i> Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 812.	4.5	57
96	Amyotrophic Lateral Sclerosis: Review. <i>Seminars in Neurology</i> , 2015, 35, 469-476.	0.5	56
97	Silencing strategies for therapy of SOD1-mediated ALS. <i>Neuroscience Letters</i> , 2017, 636, 32-39.	1.0	55
98	SOD1 aggregates in ALS: Cause, correlate or consequence?. <i>Nature Medicine</i> , 1998, 4, 1362-1364.	15.2	54
99	Modulation of actin polymerization affects nucleocytoplasmic transport in multiple forms of amyotrophic lateral sclerosis. <i>Nature Communications</i> , 2019, 10, 3827.	5.8	54
100	Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for Sporadic ALS. <i>PLoS ONE</i> , 2012, 7, e35333.	1.1	50
101	AAV gene therapy for Tay-Sachs disease. <i>Nature Medicine</i> , 2022, 28, 251-259.	15.2	49
102	Dystrophin-Associated Proteins and the Muscular Dystrophies: A Glossary. <i>Brain Pathology</i> , 1996, 6, 19-24.	2.1	46
103	Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2018, 27, 3761-3771.	1.4	45
104	A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2022, 65, 291-302.	1.0	41
105	Genetic ablation of NMDA receptor subunit NR3B in mouse reveals motoneuronal and nonmotoneuronal phenotypes. <i>European Journal of Neuroscience</i> , 2007, 26, 1407-1420.	1.2	40
106	The Role of Copy Number Variation in Susceptibility to Amyotrophic Lateral Sclerosis: Genome-Wide Association Study and Comparison with Published Loci. <i>PLoS ONE</i> , 2009, 4, e8175.	1.1	39
107	Self-Control and External Control of Mechanical Ventilation Give Equal Air Hunger Relief. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 415-420.	2.5	37
108	A common haplotype within the PON1 promoter region is associated with sporadic ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 306-314.	2.3	37

#	ARTICLE	IF	CITATIONS
109	Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	37
110	Cortical Spreading Depression Denotes Concussion Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 1008-1017.	1.7	34
111	Calpainopathy and eosinophilic myositis. <i>Annals of Neurology</i> , 2006, 59, 875-877.	2.8	33
112	Dysferlin overexpression in skeletal muscle produces a progressive myopathy. <i>Annals of Neurology</i> , 2010, 67, 384-393.	2.8	33
113	Excessive release of inorganic polyphosphate by ALS/FTD astrocytes causes non-cell-autonomous toxicity to motoneurons. <i>Neuron</i> , 2022, 110, 1656-1670.e12.	3.8	33
114	Superoxide dismutase and familial amyotrophic lateral sclerosis: New insights into mechanisms and treatments. <i>Annals of Neurology</i> , 1996, 39, 145-146.	2.8	32
115	Evaluation of the Golgi trafficking protein VPS54 (<i>wobbler</i>) as a candidate for ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 141-148.	2.3	31
116	Type 1 human poliovirus binds to human synaptosomes. <i>Annals of Neurology</i> , 1987, 21, 64-70.	2.8	30
117	50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 229-237.	2.3	29
118	Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkers. <i>Neurology</i> , 2019, 93, e1605-e1617.	1.5	29
119	Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. <i>Nature Communications</i> , 2022, 13, 2799.	5.8	28
120	A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 703-720.	1.7	24
121	Heteroplasmy in Chronic External Ophthalmoplegia: Clinical and Molecular Observations. <i>Pediatric Research</i> , 1990, 28, 542-548.	1.1	23
122	Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. <i>Journal of Neurochemistry</i> , 2005, 95, 1118-1131.	2.1	23
123	Breathlessness in Spinal Cord Injury Depends on Injury Level. <i>Journal of Spinal Cord Medicine</i> , 1999, 22, 97-101.	0.7	22
124	Analysis of a genetic defect in the TATA box of the <i>SOD1</i> gene in a patient with familial amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2007, 36, 704-707.	1.0	22
125	A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. <i>Molecular Neurodegeneration</i> , 2017, 12, 46.	4.4	22
126	A new approach for rare variation collapsing on functional protein domains implicates specific genic regions in ALS. <i>Genome Research</i> , 2019, 29, 809-818.	2.4	21

#	ARTICLE	IF	CITATIONS
127	An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 1996, 139, 10-15.	0.3	20
128	Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 369-374.	2.3	20
129	Association of UBQLN1 mutation with Brownâ€™Violettoâ€™Van Laere syndrome but not typical ALS. <i>Neurobiology of Disease</i> , 2012, 48, 391-398.	2.1	20
130	Cross-sectional associations of pulmonary function with systemic inflammation and oxidative stress in individuals with chronic spinal cord injury. <i>Journal of Spinal Cord Medicine</i> , 2016, 39, 344-352.	0.7	20
131	Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 642-654.	1.7	20
132	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a caseâ€™control study. <i>Cancer Causes and Control</i> , 2020, 31, 321-332.	0.8	20
133	Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice. <i>PLoS ONE</i> , 2022, 17, e0255710.	1.1	20
134	A Reinnervating MicroRNA. <i>Science</i> , 2009, 326, 1494-1495.	6.0	18
135	Genetic ablation of phospholipase C delta 1 increases survival in SOD1G93A mice. <i>Neurobiology of Disease</i> , 2013, 60, 11-17.	2.1	18
136	Variants in candidate ALS modifier genes linked to Cu/Zn superoxide dismutase do not explain divergent survival phenotypes. <i>Neuroscience Letters</i> , 2006, 392, 52-57.	1.0	17
137	Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 246-257.	1.8	17
138	Irreversible reduction in potassium fluxes accompanies terminal differentiation of human myoblasts to myotubes. <i>Journal of Cellular Physiology</i> , 1987, 132, 57-64.	2.0	16
139	Nucleic Acid Therapeutics for Neurological Diseases. <i>Neurotherapeutics</i> , 2019, 16, 245-247.	2.1	16
140	Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 155, 105368.	2.1	16
141	Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3â€™UTR protect against ALS. <i>Nature Neuroscience</i> , 2022, 25, 433-445.	7.1	16
142	Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 265-269.	2.3	15
143	Breathlessness and Exercise in Spinal Cord Injury. <i>Journal of Spinal Cord Medicine</i> , 1999, 22, 297-302.	0.7	13
144	Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery. <i>PLoS ONE</i> , 2007, 2, e1254.	1.1	13

#	ARTICLE	IF	CITATIONS
145	Proteolytic fragment or new gene product?. Nature, 1988, 336, 210-210.	13.7	12
146	Molecular genetic analysis of dysferlin in Japanese patients with Miyoshi myopathy. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1999, 75, 207-212.	1.6	12
147	Finding a Treatment for ALS â€” Will Gene Editing Cut It?. New England Journal of Medicine, 2018, 378, 1454-1456.	13.9	11
148	Mutation in protein disulfide isomerase A3 causes neurodevelopmental defects by disturbing endoplasmic reticulum proteostasis. EMBO Journal, 2022, 41, e105531.	3.5	11
149	Case 35-2006. New England Journal of Medicine, 2006, 355, 2132-2142.	13.9	10
150	No association ofDYNC1H1with sporadic ALS in a caseâ€control study of a northern European derived population: A tagging SNP approach. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 46-56.	2.3	9
151	Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genomeâ€wide association study. JGH Open, 2021, 5, 1363-1372.	0.7	9
152	Amyotrophic Lateral Sclerosis â€” A New Role for Old Drugs. New England Journal of Medicine, 2005, 352, 1376-1378.	13.9	8
153	Endogenous retroviruses in ALS: A reawakening?. Science Translational Medicine, 2015, 7, 307fs40.	5.8	8
154	Mutant SOD1 protein increases Nav1.3 channel excitability. Journal of Biological Physics, 2016, 42, 351-370.	0.7	8
155	AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies. Trends in Molecular Medicine, 2021, 27, 520-523.	3.5	8
156	Experience in Developing a Combined Activity and Verbal Group Therapy Program with Latency-Age Boys. International Journal of Group Psychotherapy, 1975, 25, 331-337.	0.4	7
157	Binding the Abdomen Can Improve Speech in Men With Phrenic Nerve Pacers. American Journal of Speech-Language Pathology, 2002, 11, 71-76.	0.9	7
158	DNA sequence analysis of the conserved region around the SOD1 gene locus in recessively inherited ALS. Neuroscience Letters, 2009, 463, 64-69.	1.0	6
159	Imaging Net Retrograde Axonal Transport In Vivo: A Physiological Biomarker. Annals of Neurology, 2022, 91, 716-729.	2.8	6
160	Neuron Research Leaps Ahead. Science, 2008, 321, 1169-1170.	6.0	5
161	Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 492-493.	2.3	5
162	Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2019, 311, 305-312.	2.0	5

#	ARTICLE	IF	CITATIONS
163	Lipids in Airway Mucus of Acute Quadriplegic Patients. <i>Experimental Lung Research</i> , 1990, 16, 369-385.	0.5	4
164	Further analysis of KIFAP3 gene in ALS patients from Switzerland and Sweden. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 302-304.	1.1	4
165	The Dawning of a New Era in the Molecular Biology of the Muscular Dystrophies. <i>Brain Pathology</i> , 1996, 6, 17-17.	2.1	3
166	International engagement by United States academic neurology departments: A national survey. <i>Annals of Neurology</i> , 2015, 78, 150-152.	2.8	3
167	Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. <i>Journal of Neurochemistry</i> , 2006, 96, 908-908.	2.1	2
168	Amyotrophic Lateral Sclerosis: Fuel for the Corticofugal Feud. <i>Annals of Neurology</i> , 2020, 88, 682-684.	2.8	2
169	The genetics of amyotrophic lateral sclerosis. , 2005, , 758-771.		0
170	Reply to comment on: A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 785-785.	1.7	0
171	Juvenile Amyotrophic Lateral Sclerosis. , 2015, , 146-159.		0
172	Impact of Intralingual AAVrh10-miRSOD1 Injection on Respiratory Function in SOD1 G93A Mice. <i>FASEB Journal</i> , 2018, 32, 743.7.	0.2	0